Here’s why Tyro Payments (ASX:TYR) rose as much as 20% today
Nick Sundich, August 29, 2023
Tyro Payments (ASX:TYR) was the best performer amongst stocks that released FY23 results today.
What are the Best Tech stocks to invest in right now?
Check our buy/sell stock tips
Tyro Payments (ASX:TYR) delivers a good FY23 result
Tyro Payments is a EFTPOS terminal provider and is the largest non-Big Bank provider. It generated 25% growth in transaction value (to $42.6bn), a 32% increase in revenues (to $419.2m) and gross profit (to $204.3m), as well as a bottom line profit of $6m (from -$29.6m the year before).
This was the first full-year positive cash flow result as a publicly listed company.
Slower growth in FY24, but…
For FY254, Tyro guided to $45-$47.5bn transaction value and $206-$215m gross profit.
Even though both figures would represent slower growth than the year before, it seems investors were happy that it was immune to inflation, that the company’s new operating model was paying off and most importantly, that terminal outages and the subsequent furore from customers appears over.
Stocks Down Under Concierge is here to help you pick winning stocks!
The team at Stocks Down Under have been in the markets since the mid-90s and we have gone through many ups and downs. We have written about every sector, including Semiconductors!
Our Concierge BUY and SELL service picks the best stocks on ASX. We won’t just tell you what to buy – we give you a buy range, price target and stop loss level in order to maximise total returns. And we will only recommend very high conviction stocks where substantial due diligence has been conducted.
Our performance is well ahead of the ASX200 and All Ords.
You can try out Concierge … for FREE.
GET A FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…
CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know
In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…